Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Breast cancer experts review data from the virtual San Antonio Breast Cancer Symposium 2020 in hormone epidermal growth factor receptor 2-positive breast cancer, then discuss the DESTINY-Breast01, HER2CLIMB, and NALA trials.

Data from the following abstracts are discussed:

• “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer” (Modi et al, 2020)

• “GS1-03. [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)” (Krop et al, SABCS 2019)

• “PD3-06. Updated Results From DESTINY-Breast01, A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic BreastCancer” (Modietal, SABCS 2020)

• “CNS Metastases in HER2-Positive Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan: DESTINY-Breast01 Subgroup Analyses (Jerusalem et al, ESMO Breast 2020)

• “Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer” (Murthy et al, 2020)

• “Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)” (Curigliano et al, ESMO Breast 2020, 137O)

• “Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases (HER2CLIMB)” (Lin et al, ASCO 2020)

• “PD13-04. Impact of Tucatinib on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer With Stable and Active Brain Metastases” (Wardley et al, SABCS 2020 PD-1304)

• “Neratinib + Capecitabine Versus Lapatinib + Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Findings From the Multinational, Randomized, Phase III NALA Trial” (Saura et al, ASCO 2019)

• “PS9-02. Neratinib + Capecitabine Sustains Health-Related Quality of Life (HRQoL) While Improving Progression-Free Survival (PFS) in Patients With HER2-Positive Metastatic Breast Cancer and ≥2 Prior HER2-Directed Regimens” (Moy et al, SABCS 2020 PS9-02)

• “Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-Low Breast Cancer That Has Spread or Cannot Be Surgically Removed [DESTINY-Breast04]” (NCT03734029)